We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bacterial Vaginosis Assessed By Molecular Methods

By LabMedica International staff writers
Posted on 11 May 2016
Bacterial vaginosis (BV) is an aberrant state of the vaginal microbiota, which is characterized by a depletion of lactobacilli, an increased diversity of the bacterial population and an elevated pH. It is one the most common vaginal syndromes in fertile, premenopausal and pregnant women.

Women are most often diagnosed with bacterial vaginosis (BV) using microscopy based on Nugent scoring or Amsel criteria; however, the accuracy is less than optimal. To confirm the identity of known BV-associated composition profiles and evaluate indicators for BV, three molecular methods have been assessed.

Microbiologists at the Vrije Universiteit (Amsterdam, The Netherlands) and their colleagues studied the vaginal microbiota of 40 subjects, of which 20 BV-negative and 20 BV-positive, by selection of low (0–3) and high (7–10) Nugent scores, respectively. A standard cervical examination was performed and a cotton swab was used to remove abundant mucus prior to the collection of a sample for Chlamydia trachomatis and Neisseria gonorrhoeae screening. The diagnosis of BV was based on the Nugent Gram stain and the presence of three Amsel criteria characteristic vaginal discharge, clue cells, and positive amine test.

DNA was isolated and sequence analysis was performed on a 454 GS-FLX-Titanium Sequencer (454 Life Sciences, Branford, CT, USA). Evaluation of indicators for BV was carried out by 16S ribosomal ribonucleic acid (rRNA) amplicon sequencing of the V5-V7 region, a tailor-made 16S rRNA oligonucleotide-based microarray, and a polymerase chain reaction (PCR)-based profiling technique termed IS-profiling, which is based on fragment variability of the 16S-23S rRNA intergenic spacer region. The amplification of the IS-regions was performed with the IS-pro assay (IS-Diagnostics, Amsterdam, the Netherlands).

Analysis of the bacterial communities by 16S rRNA amplicon sequencing revealed two clusters in the BV negative women, dominated by either Lactobacillus iners or L. crispatus and three distinct clusters in the BV positive women. In the former, there was a virtually complete, negative correlation between L. crispatus and L. iners. BV positive subjects showed cluster profiles that were relatively high in bacterial species diversity and dominated by anaerobic species, including Gardnerella vaginalis, and those belonging to the Families of Lachnospiraceae and Leptotrichiaceae. Accordingly, the Gini-Simpson index of species diversity, and the relative abundance Lactobacillus species appeared consistent indicators for BV.

The authors concluded that an affordable and simple molecular test showing a depletion of the genus Lactobacillus in combination with an increased species diversity of vaginal microbiota could serve as an alternative and practical diagnostic method for the assessment of BV. The study was published on April 23, 2016, in the joournal BMC Infectious Diseases.

Related Links:
Vrije Universiteit
454 Life Sciences
IS-Diagnostics
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
Portable POCT Blood Gas Analyzer
BD100
Automated Urinalysis Solution
UN-9000

Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more